Letaplimab represents a novel clinical strategy for treating complement-mediated illnesses. This biologic targets C1q, a essential factor of the complement system, aiming to inhibit its first triggering. Preliminary https://stevesazl055471.mpeblog.com/73646184/letaplimab-a-innovative-therapeutic-strategy